Non-Commercial Research and Development Sample Clauses

Non-Commercial Research and Development. Unless expressly permitted by this Section 2.1(c), neither Transferee shall have (and neither Transferee shall transfer to any Permitted Transferee) any right or license to, and shall not, export, or assist with or participate in any way in the exportation of, any assigned, licensed, or sublicensed property, including the Compound or Covered Products, outside the Territory. Notwithstanding the foregoing, nothing in this Agreement shall preclude Transferee or a Permitted Transferee from importing or exporting the Compound or Covered Products to Third Parties outside the Territory solely for non-clinical Development (i.e., Development that is not a Clinical Trial or that otherwise involves administration of the Compound or Covered Product to a human subject, including preclinical studies), but in each case only with the prior written permission of Company, which permission shall not be unreasonably refused, conditioned, delayed or withheld. In the context of academic or university research supported by Transferee or a Permitted Transferee, it is agreed that such research shall be conducted pursuant to a written materials transfer agreement (“MTA”) (i) that specifically prescribes the non-clinical Development to be conducted; (ii) the Transferee or the Permitted Transferee provides only quantities of the Compound or Covered Product sufficient to conduct the research described in the corresponding MTA; (iii) the MTA provides that Company shall have an irrevocable, royalty-free, fully paid-up worldwide exclusive license, including the right to grant and authorize sublicenses, to any discovery, invention, or other technological advance that results from research using a Compound or a Covered Product, for any and all purposes outside the Territory; and (iv) Company (and the successors and assigns of Company) is designated in the MTA as an intended third party beneficiary having the right and authority to independently and without prior notice or permission, enforce all rights of Company pursuant to the applicable MTA.
Sample 1Sample 2
AutoNDA by SimpleDocs

Related to Non-Commercial Research and Development

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Business Development Company Buyer is a business development company as defined in Section 202(a)(22) of the Investment Advisors Act of 1940.

  • Business Development Provide advice and assistance in business growth and development of Party B. 业务发展。对乙方的业务发展提供建议和协助。

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Status as Business Development Company The Borrower is an “investment company” that has elected to be regulated as a “business development company” within the meaning of the Investment Company Act and qualifies as a RIC.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

Time is Money Join Law Insider Premium to draft better contracts faster.